Value Investor
Start free

MediWound

MDWD on Nasdaq. Medicinal chemicals & botanical products. Market value $175m.

Watch this stockFree. We tell you when something changes.

This company reports once a year (it is based outside the US), so every figure comes from its annual report for the year to December 2025.

We can't read total debt from the filing, so debt is left out.

Cash flow or capital spending isn't reported, so free cash flow is unknown.

Should I look at this?

Not a fit for our list right now

Why it could be worth it

What to watch out for

See Health care stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
annual report to December 2025
n/a

We could not compute this from the filings.

Price to profit
annual report to December 2025
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: not known. Price score: not known. Our list needs 70 on quality and 60 on price.

$13.15 a share, 5% above its 1-year low

Over the past year the price has ranged from $12.52 to $20.03.

Prices from Tuesday’s close (6 October).

Five years of cash, in billions

n/a
n/a
n/a
n/a
n/a
20212022202320242025
Revenue
n/an/an/an/an/a
Operating margin
n/an/an/an/an/a
Debt to equity
n/an/an/an/an/a
Shares outstanding
0.03bn0.01bn0.01bn0.01bn0.01bn

Health checks

  • Free cash flow positiveNot enough data
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)Not enough data
  • Profit backed by cash (accruals)Not enough data
  • DebtUnknown
  • Revenue growth, five yearsUnknown
  • Buying back its own sharesYes, 53% fewer since 2021

Dates

Next results (estimated)
n/a
Last annual report (10-K)
5 March 2026
Next quarterly (estimated, 10-Q)
n/a

Who owns it

None of the long-term investors we follow own it. 79 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

5 investors own more than 5%.

  • Access Industries Holdings LLC
    Passive investor
    at least 11.6%
    (filed with 6 related holders)
    Since 30 September 2025
  • HOLD Alapkezelo Zrt.
    Passive investor
    10.4%+2.3 pts
    Since 27 August 2026
  • Rosalind Advisors, Inc.
    Passive investor
    at least 7.0%0.0 pts
    (filed with 3 related holders)
    Since 31 December 2025
  • at least 6.0%
    (filed with 2 related holders)
    Since 31 December 2025
  • 5.0%−0.5 pts
    Since 30 June 2026

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 3 insiders bought $142,690 of shares on the open market. 2 sold $82,072.

  • Rubinstein Samuel
    Director
    Sold
    Date
    1 September 2026
    Shares
    525
    Price
    $12.72
    Value
    $6,678
  • Rubinstein Samuel
    Director
    Bought
    Date
    1 September 2026
    Shares
    525
    Price
    $12.62
    Value
    $6,626
  • Hess Shmuel
    COO & Chief Commercial Officer
    Sold
    Date
    27 August 2026
    Shares
    3,958
    Price
    $12.92
    Value
    $51,149
  • Hess Shmuel
    COO & Chief Commercial Officer
    Sold
    Date
    26 August 2026
    Shares
    1,865
    Price
    $13.00
    Value
    $24,245
  • SHAMIR NACHUM
    Director
    Bought
    Date
    3 June 2026
    Shares
    6,000
    Price
    $14.00
    Value
    $83,997
  • Fox David Morton
    Director
    Bought
    Date
    1 June 2026
    Shares
    3,537
    Price
    $14.11
    Value
    $49,918
  • Rubinstein Samuel
    Director
    Bought
    Date
    29 May 2026
    Shares
    150
    Price
    $14.33
    Value
    $2,150

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

MediWound doesn’t file a US annual report (10-K), so we haven’t checked it.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.